Conference Correspondent 

Breast cancer survivors may test positive for pathogenic germline variants 10 years after their original diagnosis. Germline genetic testing may be an important tool for managing care.

Improved understanding of potential risk factors associated with weight gain will allow identification of at-risk patients and intervention for improved outcomes.

The VA CARES program provides coordinated cancer care for veterans prescribed oral antineoplastic therapies who may lack access to comprehensive medication management resources.

Alpelisib plus fulvestrant combination therapy improves progression-free survival while maintaining effectiveness in patients with HR-positive/HER2-negative advanced breast cancer in a French early access study.

Metabolic syndrome is associated with poor prognosis in patients with breast cancer. Identifying potential risk factors for metabolic syndrome may improve outcomes in these women.

Moderate physical activity reduced the inflammatory response triggered by neoadjuvant chemotherapy in breast cancer patients prior to surgery. The benefit appears to be lost after surgery.

Diverse factors contribute to shifts in psychosocial function in breast cancer patients after treatment. Understanding these factors provides opportunities for patients to receive more holistic care.

Actionable biomarkers associated with directed treatment to prevent or reverse symptoms in African Americans with advanced-stage breast cancer may reduce mortality rates.

The SOLAR-1 and X2101 trials demonstrate long-term disease control can be attained for ≥18 months with alpelisib plus fulvestrant in patients with hard-to-treat HR-positive/HER2-negative advanced breast cancer.

Many women with HR-positive breast cancer contend with emotional distress during prolonged adjuvant endocrine therapy. Behavioral interventions show promise as effective strategies to reduce stress and improve adherence to therapy.

Page 1 of 31


Subscribe Today!

To sign up for our newsletter or print publications, please enter your contact information below.

I'd like to receive: